Clinical significance of the CXCL8/CXCR1/R2 signalling axis in patients with invasive breast cancer.

IF 2.5 4区 医学 Q3 ONCOLOGY Oncology Letters Pub Date : 2024-04-10 DOI:10.3892/ol.2024.14393
Sebastian Stępień, Marta Smycz-Kubańska, Celina Kruszniewska-Rajs, Joanna Magdalena Gola, Jacek Kabut, Paweł Olczyk, Aleksandra Mielczarek-Palacz
{"title":"Clinical significance of the CXCL8/CXCR1/R2 signalling axis in patients with invasive breast cancer.","authors":"Sebastian Stępień, Marta Smycz-Kubańska, Celina Kruszniewska-Rajs, Joanna Magdalena Gola, Jacek Kabut, Paweł Olczyk, Aleksandra Mielczarek-Palacz","doi":"10.3892/ol.2024.14393","DOIUrl":null,"url":null,"abstract":"The C-X-C motif chemokine ligand 8 (CXCL8)-C-X-C chemokine receptor (CXCR)1/2 signalling axis is among numerous mechanisms which stimulate the immune system to defend against tumour growth and influence the tumour microenvironment to promote tumour growth. This pathway plays an important role in the development of a number of cancers including breast cancer (BC). The aim of the present study was to analyse the levels of the chemokine CXCL8 and its receptors, CXCR1 and CXCR2, in the serum of female patients with invasive BC and to assess the expression of these parameters at the mRNA level, considering molecular subtypes and degrees of cancer malignancy. The study group consisted of 62 patients with histopathologically confirmed invasive BC. The control group consisted of 18 patients with histopathologically confirmed fibroadenoma, a benign breast tumour. The levels of CXCL8, CXCR1 and CXCR2 were determined by sandwich ELISA using the CLOUD-CLONE ELISA kit. CXCL8, CXCR1 and CXCR2 transcript levels were analysed using reverse transcription-quantitative PCR. Results showed that serum CXCL8 levels in female patients with invasive BC were significantly higher compared with those in the control group (P&lt;0.05). In addition, significantly elevated CXCR1 levels were observed in luminal B human epidermal growth factor receptor 2<sup>+</sup> carcinoma compared with those in the control group. Analysis of CXCL8 in the serum of female patients with BC showed a statistically significant difference between clinical stage G1 and G2 (P&lt;0.05), G2 and G3 (P&lt;0.01), and G1 and G3 (P&lt;0.0001). On the other hand, the analysis of CXCR1 and CXCR2 levels in the serum of the patients revealed a statistically significant difference between G2 and G3 (P&lt;0.05). The current study showed that abnormalities in the immune response involving the CXCL8-CXCR1/2 signalling axis in patients with invasive BC are involved in the development of these tumours. Moreover, the demonstrated severity of changes occurring at protein level may suggest the potential usefulness of their determination as potential diagnostic markers in the clinic.","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"25 1","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2024-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Letters","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3892/ol.2024.14393","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The C-X-C motif chemokine ligand 8 (CXCL8)-C-X-C chemokine receptor (CXCR)1/2 signalling axis is among numerous mechanisms which stimulate the immune system to defend against tumour growth and influence the tumour microenvironment to promote tumour growth. This pathway plays an important role in the development of a number of cancers including breast cancer (BC). The aim of the present study was to analyse the levels of the chemokine CXCL8 and its receptors, CXCR1 and CXCR2, in the serum of female patients with invasive BC and to assess the expression of these parameters at the mRNA level, considering molecular subtypes and degrees of cancer malignancy. The study group consisted of 62 patients with histopathologically confirmed invasive BC. The control group consisted of 18 patients with histopathologically confirmed fibroadenoma, a benign breast tumour. The levels of CXCL8, CXCR1 and CXCR2 were determined by sandwich ELISA using the CLOUD-CLONE ELISA kit. CXCL8, CXCR1 and CXCR2 transcript levels were analysed using reverse transcription-quantitative PCR. Results showed that serum CXCL8 levels in female patients with invasive BC were significantly higher compared with those in the control group (P<0.05). In addition, significantly elevated CXCR1 levels were observed in luminal B human epidermal growth factor receptor 2+ carcinoma compared with those in the control group. Analysis of CXCL8 in the serum of female patients with BC showed a statistically significant difference between clinical stage G1 and G2 (P<0.05), G2 and G3 (P<0.01), and G1 and G3 (P<0.0001). On the other hand, the analysis of CXCR1 and CXCR2 levels in the serum of the patients revealed a statistically significant difference between G2 and G3 (P<0.05). The current study showed that abnormalities in the immune response involving the CXCL8-CXCR1/2 signalling axis in patients with invasive BC are involved in the development of these tumours. Moreover, the demonstrated severity of changes occurring at protein level may suggest the potential usefulness of their determination as potential diagnostic markers in the clinic.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
侵袭性乳腺癌患者体内 CXCL8/CXCR1/R2 信号轴的临床意义。
C-X-C motif趋化因子配体8(CXCL8)-C-X-C趋化因子受体(CXCR)1/2信号轴是刺激免疫系统抵御肿瘤生长并影响肿瘤微环境以促进肿瘤生长的众多机制之一。这一通路在包括乳腺癌(BC)在内的多种癌症的发病过程中发挥着重要作用。本研究的目的是分析浸润性乳腺癌女性患者血清中趋化因子CXCL8及其受体CXCR1和CXCR2的水平,并评估这些参数在mRNA水平上的表达,同时考虑到癌症的分子亚型和恶性程度。研究组由 62 名经组织病理学证实的浸润性 BC 患者组成。对照组包括18名经组织病理学确诊的乳腺纤维腺瘤(一种良性乳腺肿瘤)患者。CXCL8、CXCR1和CXCR2的水平采用夹心ELISA法测定,使用的是CLOUD-CLONE ELISA试剂盒。使用反转录定量 PCR 分析了 CXCL8、CXCR1 和 CXCR2 的转录水平。结果显示,女性浸润性BC患者血清中的CXCL8水平明显高于对照组(P<0.05)。此外,与对照组相比,在管腔 B 型人表皮生长因子受体 2+ 癌中观察到 CXCR1 水平明显升高。对女性 BC 患者血清中 CXCL8 的分析表明,临床分期 G1 和 G2(P<0.05)、G2 和 G3(P<0.01)以及 G1 和 G3(P<0.0001)之间的差异有统计学意义。另一方面,对患者血清中 CXCR1 和 CXCR2 水平的分析表明,G2 和 G3 之间的差异具有统计学意义(P<0.05)。目前的研究表明,侵袭性 BC 患者涉及 CXCL8-CXCR1/2 信号轴的免疫反应异常与这些肿瘤的发展有关。此外,蛋白质水平变化的严重程度表明,将其测定为潜在的诊断标记物在临床上可能很有用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Oncology Letters
Oncology Letters ONCOLOGY-
CiteScore
5.70
自引率
0.00%
发文量
412
审稿时长
2.0 months
期刊介绍: Oncology Letters is a monthly, peer-reviewed journal, available in print and online, that focuses on all aspects of clinical oncology, as well as in vitro and in vivo experimental model systems relevant to the mechanisms of disease. The principal aim of Oncology Letters is to provide the prompt publication of original studies of high quality that pertain to clinical oncology, chemotherapy, oncogenes, carcinogenesis, metastasis, epidemiology and viral oncology in the form of original research, reviews and case reports.
期刊最新文献
Immunotherapy beyond progression following first‑line chemotherapy plus immunotherapy in advanced non‑small cell lung cancer: A retrospective study. Molecular characteristics, clinical significance and cancer‑immune interactions of pyroptosis‑related genes in colorectal cancer. The role of IL‑17, IFN‑γ, 4‑1BBL and tumour‑infiltrating lymphocytes in the occurrence, development and prognosis of pancreatic cancer. Network pharmacology and molecular docking reveal the mechanism of action of Bergapten against non‑small cell lung cancer. A novel algorithm for the detection of microsatellite instability in endometrial cancer using next‑generation sequencing data.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1